Quest Diagnostics Incorporated (DGX) |
|
140.06 4.67 (3.45%)
|
03-24 16:03 |
|
Open: |
135.59 |
Pre. Close: |
135.39 |
|
High:
|
141.28 |
Low:
|
134.96 |
|
Volume:
|
1,655,109 |
Market Cap:
|
15,592(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:25:18 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 173.93  One year: 203.16 |
| Support: |
Support1: 137.43 Support2: 130.33 |
| Resistance: |
Resistance1: 148.91 Resistance2: 173.93 |
| Pivot: |
135.19  |
| Moving Average: |
MA(5): 135.71 MA(20): 136.22
MA(100): 146.01 MA(250): 138.6 |
| MACD: |
MACD(12,26): -2.1 Signal(9): -2.8 |
| Stochastic oscillator: |
%K(14,3): 57.6 %D(3): 46.8 |
| RSI: |
RSI(14): 54.7 |
| 52-week: |
High: 158.33 Low: 120.4 |
| Average Vol(K): |
3-Month: 1,169 (K) 10-Days: 1,351 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DGX ] has closed below upper band by 1.1%. Bollinger Bands are 11.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
141.45 - 141.98 |
141.98 - 142.4 |
|
Low:
|
133.57 - 134.22 |
134.22 - 134.74 |
|
Close:
|
139.07 - 140.09 |
140.09 - 140.91 |
|
Company Description |
|
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. |
Headline News |
Tue, 21 Mar 2023
First-of-Its-Kind Post-COVID-19 Panels Available at questhealth.com - Quest Diagnostics Newsroom
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Joel Greenblatt - 3 ... - Nasdaq
Thu, 16 Mar 2023
Quest Diagnostics to Discuss Strategic Priorities to Drive Growth and ... - Quest Diagnostics Newsroom
Mon, 06 Mar 2023
Investing in Quest Diagnostics (NYSE:DGX) five years ago would have delivered you a 48% gain - Simply Wall St
Tue, 14 Feb 2023
Quest Diagnostics and NewYork-Presbyterian Agree to Laboratory ... - Quest Diagnostics Newsroom
Mon, 13 Feb 2023
Quest Diagnostics to Host Investor Day on March 16, 2023 - Quest Diagnostics Newsroom
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
111 (M) |
| Shares Float |
110 (M) |
|
% Held by Insiders
|
0.7 (%) |
|
% Held by Institutions
|
93.7 (%) |
|
Shares Short
|
3,320 (K) |
|
Shares Short P.Month
|
2,740 (K) |
Stock Financials |
|
EPS
|
7.88 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
53.09 |
|
Profit Margin (%)
|
9.5 |
|
Operating Margin (%)
|
15.6 |
|
Return on Assets (ttm)
|
7.3 |
|
Return on Equity (ttm)
|
16.1 |
|
Qtrly Rev. Growth
|
-15 |
|
Gross Profit (p.s.)
|
31.17 |
|
Sales Per Share
|
88.75 |
|
EBITDA (p.s.)
|
17.87 |
|
Qtrly Earnings Growth
|
-71.7 |
|
Operating Cash Flow
|
1,720 (M) |
|
Levered Free Cash Flow
|
1,050 (M) |
Stock Valuations |
|
PE Ratio
|
17.75 |
|
PEG Ratio
|
-2 |
|
Price to Book value
|
2.63 |
|
Price to Sales
|
1.57 |
|
Price to Cash Flow
|
9.06 |
Stock Dividends |
|
Dividend
|
0.66 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.4% |
|
Dividend Pay Date
|
2022-02-01 |
|
Ex-Dividend Date
|
2022-01-17 |
|
Your Ad Here
|
|
